|Bid||1.06 x 1400|
|Ask||1.09 x 1000|
|Day's Range||1.06 - 1.15|
|52 Week Range||0.98 - 6.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
The second-quarter earnings season has produced plenty of shockers, and pharmaceutical company MannKind (NASDAQ:MNKD) is one of them. After posting a disastrous miss on the top-line, and financial metrics that implied a viability concern, MNKD stock tanked more than 23%. In the year-ago quarter, MannKind posted a 35-cent EPS loss.
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / U.S. equities finished mostly higher on Thursday as Apple breaching the 1 trillion dollar valuation plateau offset the ongoing trade concerns between the U.S. ...
MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and -18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation (NASDAQ:MNKD) reported its latest quarterly earnings results after the bell Thursday, which came in ahead of its year-ago results on both its revenue and loss. For its second quarter of fiscal 2018, the biopharmaceutical company amassed net revenue of $3.8 million for its diabetes treatment Afrezza, marking a 142% growth compared to its revenue of $1.5 million from the year-ago quarter. The MannKind Corporation medication is an inhaled insulin treatment for Type 1 and Type 2 Diabetes.
On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. In the final minutes of ...
2 Q 2018 Afrezza Net Revenue was $3.8 million; 142% growth versus 2 Q 2017 2 Q 2018 Afrezza TRx grew 71% versus 2 Q 2017 Debt principal reduced by $42.6 million, or 27%, year-to-date Successfully completed ...
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement for Afrezza® with Tanner Pharma Group, a global provider of integrated specialty access solutions. The agreement names Tanner as a distributor of Afrezza® outside of the United States in regions the product is not yet registered.
WESTLAKE VILLAGE, Calif., July 27, 2018-- MannKind Corporation will host a conference call to discuss the 2018 second quarter and year-to-date financial results and other corporate developments at 5:00 ...
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it is set to join the broad-market Russell 3000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on June 25, 2018, according to the final list of additions posted on June 22, 2018. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of May 11, 2018, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
MannKind Corporation (MNKD) announced that additional data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) will be presented in an oral presentation later today at the American Diabetes Association’s (ADA) 78th Scientific Sessions. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza.
WESTLAKE VILLAGE, Calif., June 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) were released today at the American Diabetes Association’s 78th Scientific Sessions, being held June 22-26, 2018, in Orlando, Florida. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza.
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes. MannKind’ s Chief Medical Officer Presenting New Afrezza ® Data Released at American Diabetes Association’ ...
MannKind Corporation (MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administration.
WESTLAKE VILLAGE, Calif., June 05, 2018-- MannKind Corporation has established a stock purchase plan that provides MannKind’ s directors and executive officers with a way to purchase shares of common stock ...